Gout - Clinical trials 

  • Clinical trials

Clinical trials for Gout

Information provided by WHO International Clinical Trials Registry

The clinical trials below are relevant to Gout. For all clinical trials, go to clinical trials search

This list shows clinical trials for Gout

Search result filters
Recruitment status
Trials for children:
Country of trial:

You have searched for the following terms

  • Gout
Title Recruitment status Location
Febuxostat versus Allopurinol Streamlined Trial (FAST) Recruiting United Kingdom
Postmarketing Study for Determine Performance of the SIGMA HP® PARTIAL KNEE SYSTEM Recruiting United Kingdom
A 24-week, dose-ranging, multi-center, double-blind, double-dummy, active-controlled study to evaluate canakinumab (ACZ885) for prophylaxis of signs and symptoms of acute flares in chronic gout patients initiating allopurinol therapy - H2251 Not Recruiting United Kingdom
A 24-week, dose-ranging, multi-center, double-blind, double-dummy, active-controlled study to evaluate canakinumab (ACZ885) for prophylaxis of signs and symptoms of acute flares in chronic gout patients initiating allopurinol therapy - H2251 Not Recruiting United Kingdom
A 24-week open-label, multicenter, follow-up and extension study to CACZ885H2251, to assess safety, tolerability and efficacy of canakinumab (ACZ885) in patients with gout who are given canakinumab at the time of gout flare. - H2251E1 Not Recruiting United Kingdom
Targeted Dose Finding of Canakinumab (ACZ885) for Management of Acute Flare in Refractory or Contraindicated Gout Patients Not recruiting United Kingdom
A 24-week open-label, multicenter, follow-up and extension study to CACZ885H2251, to assess safety, tolerability and efficacy of canakinumab (ACZ885) in patients with gout who are given canakinumab at the time of gout flare. - H2251E1 Not Recruiting United Kingdom
Randomized, Double-Blind, Multicenter, Placebo-Controlled, Safety and Efficacy Study of RDEA594 Versus Placebo in the Treatment of Hyperuricemia in Patients with Gout Not Recruiting United Kingdom
A 24-week open-label, multicenter, follow-up and extension study to CACZ885H2251, to assess safety, tolerability and efficacy of canakinumab (ACZ885) in patients with gout who are given canakinumab at the time of gout flare. - H2251E1 Not Recruiting United Kingdom
Development of a complex intervention for the treatment of gout in primary care Not recruiting United Kingdom
  • Link to Directgov – public services all in one place
  • The Information Standard - Certified member